New research shows that Ozempic and similar drugs reduce opioid overdoses by 40% and alcohol intoxication by 50% in people ...

A new study reveals that glucagon-like peptide-1 receptor agonists (GLP-1), which include weight loss and diabetes med ...

Facial volume loss and increased skin laxity were significant in the mid-cheek region after major weight loss, resulting in accelerated facial aging.

Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years according to ...

The use of GLP-1 RAs is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic procedures.

Ozempic and other semaglutide medications for weight loss have been linked to hair loss on social media. Experts share who is ...

Weight loss drugs have risen in popularity in the recent years, but a disconnect remains between those who need the drugs and ...

Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have comorbid type 2 diabetes, high body mass index, and a previous metformin ...

As pharmaceutical treatments, such as GLP-1 agonists, are reaching weight reductions of magnitudes close to those achieved through bariatric surgery, the concerns regarding a possible adverse impact ...

Expanding access to new, highly effective weight-loss medications could prevent more than 40,000 deaths a year in the United ...

Newer weight loss drugs are cost effective in the long term only when combined with bariatric weight loss surgery, according ...

A large study of veterans with type 2 diabetes finds better short-term kidney outcomes with use of SGLT2 inhibitors vs GLP-1 receptor agonists.